Pet owners in the United States are injecting aging dogs with BPC-157, one half of the Wolverine stack, after short-form videos showed an 11-year-old dog regaining mobility over several weeks. The clips do not disclose the peptide's source, the administered dose, or whether a veterinarian supervised the injection. Two veterinary clinicians publicly warned within days that no published trial has established a safe dose of BPC-157 or its companion peptide TB-500 in any animal species.
The FDA advisory panel that voted in late July 2026 to recommend these compounds for human compounding pharmacies did not evaluate them for dogs or other animals. The agency's Center for Veterinary Medicine, which approves and regulates new animal drugs, was not part of the advisory process. For pet owners encountering these peptides through wellness podcasts rather than a veterinary hospital, the distinction between "available at a human compounding counter" and "tested for a 30-kilogram Labrador" remains invisible.
What the July vote actually covers
Figure 1: The July FDA compounding recommendation opened a human pharmacy pathway, but left canine dosing and safety thresholds for BPC-157 and TB-500 undefined.
The advisory committee voted 8-6 to recommend adding BPC-157 to the 503A Bulks List, which would permit compounding pharmacies to prepare the peptide under a pharmacist's supervision for human patients, as CNN reported. TB-500 also received the panel's recommendation, The Atlantic confirmed, alongside KPV and MOTS-c. Neither vote constitutes FDA approval. Both peptides remain classified as research-use-only chemicals in the United States, meaning they cannot legally be marketed for human or animal consumption until the agency issues a final bulks-list determination.
Jamie Richardson, head of veterinary medicine at Small Door Veterinary, told Men's Health that a dog's metabolism and biology differ significantly from a human's and that what a self-experimenting fitness enthusiast tolerates might prove toxic to a Golden Retriever, as Ladbible reported on August 25. Andrew Bugbee, chief medical officer at Texas A&M University's Small Animal Teaching Hospital, identified the absence of safety data as the central concern. Neither clinician has published or reviewed a controlled trial of BPC-157 in dogs.
The access gap that gray markets fill
The vote addresses a human-pharmacy pathway. It does not create one for animals. Pet owners who cannot access a veterinary prescriber willing to compound an unapproved peptide, or who cannot afford the consultation, turn to online retailers selling research-grade vials with no species-specific dosing guidance. Whether these peptides are legal in a veterinary context remains unresolved until the FDA issues its final determination.
The oversight infrastructure that would govern even the human compounding route is thin. The Guardian's July investigation found that 81 percent of newly registered bulk compounding facilities had not yet been inspected by FDA staff as of mid-2025, and compounding pharmacies do not require pre-market inspection before dispensing. For a veterinary patient whose dosing would fall outside even that limited human framework, supervision thins further.
Dr. Ryan Wooden, owner and lead pharmacist at Collierville Compounding Pharmacy in Tennessee, told WREG he expects state pharmacy boards to begin discussing peptide compounding protocols in the coming months. No FDA timeline exists for final rulemaking. Until those decisions arrive, pet owners replicating the protocol seen in viral clips are dosing an unapproved compound in a species for which no safety threshold has been published, and Bugbee's warning stands as the closest thing to clinical guidance available.
